Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Clin Lung Cancer. 2017 Feb 9;18(5):559–564. doi: 10.1016/j.cllc.2017.01.012

Table 3.

Predictors of Durable Clinical Benefit

Predictor With DCB (10) Without DCB (10) P
Average Duration of Response, mo 12.9 (9.9–15.9) 2.7 (0.9–4.3) <.001
Mean Age, y 60.8 (55.7–65.9) 64.4 (59.4–69.4) .09
Smoking: Mean, Pack-Years 37.6 (13.2–61) 71.3 (50.2–92.4) .007
Mean CCI 3.1 (1.9–5.3) 3.3 (1.8–4.8) .64
Adenocarcinoma, n 7 3 .34
>1 Previous Chemotherapy Regimen, n 7 2 .15
Mean Total Radiation Received, Gy 50 (2.4–97.6) 39.8 (11.7–67.9) .88
Development of IRAE, n 3 0 .22

Values in parentheses represent 95% CIs.

Abbreviations: CCI = Charlson comorbidity index; IRAE = immune-related adverse event.